Обзор эффективности применения спектроскопии ядерного магнитного резонанса для диагностики рака предстательной железы

Рак предстательной железы (РПЖ) – самое распространенное злокачественное новообразование в России среди мужчин и одно из самых распространенных в мире. Диагностика РПЖ, контроль течения и оценка прогноза развития заболевания выполняются с помощью комплекса обследований: лабораторных, инструментальных, а также различных номограмм. Существующие методы диагностики РПЖ ограничены по чувствительности и специфичности, поэтому поиск новых методов диагностики является актуальной задачей. Одним из перспективных диагностических подходов может стать спектроскопия ядерного магнитного резонанса (ЯМР), с помощью которой выполняется поиск ассоциированных со злокачественным новообразованием метаболитов в биологических жидкостях организма. По данным ряда исследований, РПЖ ассоциирован с изменениями концентраций различных метаболитов в сыворотке или плазме крови. В настоящем обзоре приведены результаты исследований, в которых сообщается о высокой эффективности использования ЯМР-спектроскопии для диагностики РПЖ с использованием для анализа сыворотки или плазмы крови

1. Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 262 с.

2. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834

3. Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13(3s2–1):640–60. DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660

4. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268–78. DOI: 10.1038/nrc2351

5. Кушлинский К.Е., Стороженко И.В., Сергеева Н.С. и др. Рак предстательной железы и простат-специфический антиген. Российский онкологический журнал 2000;(1):44–8.

6. Sundaresan V.M., Smani S., Rajwa P. et al. Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol 2025;43(1):41–8. DOI: 10.1016/j.urolonc.2024.06.003

7. Haythorn M.R., Ablin R.J. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med 2011;5(4):515–26. DOI: 10.2217/bmm.11.53

8. Ploussard G., Nicolaiew N., Marchand C. et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol 2014;65(1):154–61. DOI: 10.1016/j.eururo.2012.05.049

9. De la Taille A., Antiphon P., Salomon L. et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003;61(6):1181–6. DOI: 10.1016/s0090-4295(03)00108-0

10. Ahmed H.U., El-Shater Bosaily A., Brown L.C. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389(10071):815–22. DOI: 10.1016/S0140-6736(16)32401-1

11. Loeb S., Vellekoop A., Ahmed H.U. et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64(6):876–92. DOI: 10.1016/j.eururo.2013.05.049

12. Van der Kwast T.H., Roobol M.J. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013;10(8):473–82. DOI: 10.1038/nrurol.2013.112

13. Valerio M., Donaldson I., Emberton M. et al. Detection of clinically significant prostate cancer using magnetic resonance imaging – ultrasound fusion targeted biopsy: a systematic review. Eur Urol 2015;68(1):8–19. DOI: 10.1016/j.eururo.2014.10.026

14. Mlynárik V. Introduction to nuclear magnetic resonance. Anal Biochem 2017;529:4–9. DOI: 10.1016/j.ab.2016.05.006

15. Bleaney B. Jubilees of radio-frequency spectroscopy. Notes Rec R Soc Lond 1997;51(2):317–26.

16. Günther H. NMR spectroscopy: basic principles, concepts and applications in chemistry. John Wiley & Sons, 2013.

17. Cacciatore S., Loda M. Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci 2015;1346(1):57–62. DOI: 10.1111/nyas.12775

18. Nicholson J.K., Lindon J.C., Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29(11):1181–9. DOI: 10.1080/004982599238047

19. Jordan K.W., Nordenstam J., Lauwers G.Y. et al. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum 2009;52(3):520–5. DOI: 10.1007/DCR.0b013e31819c9a2c

20. Trock B.J. Application of metabolomics to prostate cancer. Urol Oncol 2011;29(5):572–81. DOI: 10.1016/j.urolonc.2011.08.002

21. Ren J.L., Zhang A.H., Kong L., Wang X.J. Advances in mass spectrometry-based metabolomics for investigation of metabolites. RSC Adv 2018;8(40):22335–50. DOI: 10.1039/c8ra01574k

22. Nagana Gowda G.A., Gowda Y.N., Raftery D. Expanding the limits of human blood metabolite quantitation using NMR spectroscopy. Anal Chem 2015;87(1):706–15. DOI: 10.1021/ac503651e

23. Overview of NMR spectroscopy-based metabolomics: opportunities and challenges. In: NMR-Based Metabolomics: Methods and Protocols. Eds.: G.A. Gowda, D. Raftery. Vol. 2037. New York, NY, USA: Humana Press, 2019. Pp. 3–14.

24. Dumas M.E., Maibaum E.C., Teague C. et al. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem 2006;78(7):2199–208. DOI: 10.1021/ac0517085

25. Sharma U., Jagannathan N.R. Metabolism of prostate cancer by Magnetic Resonance Spectroscopy (MRS). Biophys Rev 2020;12(5):1163–73. DOI: 10.1007/s12551-020-00758-6

26. Lima A.R., Bastos Mde L., Carvalho M., Guedes de Pinho P. Biomarker discovery in human prostate cancer: an update in metabolomics studies. Transl Oncol 2016;9(4):357–70. DOI: 10.1016/j.tranon.2016.05.004

27. Wishart D.S., Djoumbou Feunang Y., Marcu A. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018;46(D1):D608–17. DOI: 10.1093/nar/gkx1089

28. Nagana Gowda G.A., Raftery D. Biomarker discovery and translation in metabolomics. Curr Metabolomics 2013;1(3):227–40. DOI: 10.2174/2213235X113019990005

29. Dakubo G.D., Parr R.L., Costello L.C. et al. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59(1):10–6. DOI: 10.1136/jcp.2005.027664

30. Costello L.C., Feng P., Milon B. et al. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 2004;7(2):111–7. DOI: 10.1038/sj.pcan.4500712

31. Costello L.C., Franklin R.B. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys 2016;611:100–12. DOI: 10.1016/j.abb.2016.04.014

32. Eidelman E., Twum-Ampofo J., Ansari J., Minhaj Siddiqui M. The metabolic phenotype of prostate cancer. Front Oncol 2017;7:131. DOI: 10.3389/fonc.2017.00131

33. Andersen M.K., Giskeødegård G.F., Tessem M.B. Metabolic alterations in tissues and biofluids of patients with prostate cancer. Curr Opin Endocrine Metabol Res 2020;10:23–8.

34. Kwon H., Oh S., Jin X. et al. Cancer metabolomics in basic science perspective. Arch Pharm Res 2015;38(3):372–80. DOI: 10.1007/s12272-015-0552-4

35. Warburg O. On the origin of cancer cells. Science 1956;123(3191):309–14. DOI: 10.1126/science.123.3191.309

36. Sadeghi R.N., Karami-Tehrani F., Salami S. Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. Tumour Biol 2015;36(4):2893–2905. DOI: 10.1007/s13277-014-2919-4

37. Twum-Ampofo J., Fu D.X., Passaniti A. et al. Metabolic targets for potential prostate cancer therapeutics. Curr Opin Oncol 2016;28(3):241–7. DOI: 10.1097/CCO.0000000000000276

38. Dueregger A., Schöpf B., Eder T. et al. Differential utilization of dietary fatty acids in benign and malignant cells of the prostate. PLoS One 2015;10(8):e0135704. DOI: 10.1371/journal.pone.0135704

39. Zadra G., Loda M. Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities. Cold Spring Harb Perspect Med 2018;8(10):a030569. DOI: 10.1101/cshperspect.a030569

40. Lloyd S.M., Arnold J., Sreekumar A. Metabolomic profiling of hormone-dependent cancers: a bird’s eye view. Trends Endocrinol Metab 2015;26(9):477–85. DOI: 10.1016/j.tem.2015.07.001

41. Schipper R.G., Romijn J.C., Cuijpers V.M.J.I., Verhofstad A.A.J. Polyamines and prostatic cancer. Biochem Soc Trans 2003;31(2):375–80. DOI: 10.1042/bst0310375

42. Feun L., You M., Wu C.J. et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14(11):1049–57. DOI: 10.2174/138161208784246199

43. Qiu F., Huang J., Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett 2015;364(1):1–7. DOI: 10.1016/j.canlet.2015.04.020

44. Wang H., Zhang L., Fu Y. et al. CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate 2016;76(2):140–50. DOI: 10.1002/pros.23104

45. Mithal P., Allott E., Gerber L. et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol 2014;21(12):1209–14. DOI: 10.1111/iju.12571

46. Tennakoon J.B., Shi Y., Han J.J. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 2014;33(45):5251–61. DOI: 10.1038/onc.2013.463

47. Zadra G., Photopoulos C., Tyekucheva S. et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014;6(4):519–38. DOI: 10.1002/emmm.201302734

48. Sanli T., Steinberg G.R., Singh G., Tsakiridis T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 2014;15(2):156–69. DOI: 10.4161/cbt.26726

49. Kumar D., Gupta A., Mandhani A., Narain Sankhwar S. NMR spectroscopy of filtered serum of prostate cancer: a new frontier in metabolomics. Prostate 2016;76(12):1106–19. DOI: 10.1002/pros.23198

50. Zniber M., Vahdatiyekta P., Huynh T.P. Discrimination of serum samples of prostate cancer and benign prostatic hyperplasia with 1 H-NMR metabolomics. Anal Methods 2024;16(41):7043–53. DOI: 10.1039/d4ay01109k

51. Kumar D., Gupta A., Mandhani A., Narain Sankhwar S. Metabolomics-derived prostate cancer biomarkers: fact or fiction? J Proteome Res 2015;14(3):1455–64. DOI: 10.1021/pr5011108

52. Gomez-Cebrian N., García-Flores M., Rubio-Briones J. et al. Targeted metabolomics analyses reveal specific metabolic alterations in high-grade prostate cancer patients. J Proteome Res 2020;19(10):4082–92. DOI: 10.1021/acs.jproteome.0c00493

53. Zhang X., Xia B., Zheng H. et al. Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis. J Translat Med 2022;20(1):275. DOI: 10.1186/s12967-022-03478-5